Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.
All Science Journal Classification (ASJC) codes